The Moorfields DMO Dataset is a longitudinal dataset consisting of routinely collected imaging and clinical metadata from patients receiving treatment for Diabetic Macular Oedema (DMO) at Moorfields Eye Hospital NHS Foundation Trust, from 2004 to the present.
This dataset encompasses all patients at Moorfields Eye Hospital NHS Foundation Trust - a leading provider of eye health services in the UK and a world-class centre of excellence for ophthalmic research and education - who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) for DMO. These therapies began at Moorfields in 2013, however, the dataset will include any imaging or clinical metadata that is available for these patients prior to that time (for example in patients who were initially monitored or received other treatments prior to receiving treatment). Also of note, this dataset will include data from both eyes in each case - for example, it will include data from fellow eyes that are not receiving injections. For these reasons, the dataset will include longitudinal data from a wide range of diabetic eye disease.
Clinical metadata includes demographic information, visual acuities (predominantly measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts), diabetic retinopathy grading, and information regarding intravitreal therapies and ocular surgeries.
Imaging metadata includes colour fundus photographs, optical coherence tomography (OCT) scans (Topcon, Heidelberg), fundus autofluorescence (Heidelberg), fluorescein and indocyanine green angiography (Heidelberg).
This dataset is continuously updated. As of September 2021, it comprised of over 3,200 eyes receiving Lucentis or Eylea for DMO, over 42,700 injection episodes, and over 806,000 ophthalmic images. This is the largest single centre database from patients with DMO and covers more than a decade of follow-up for these patients.